Clinical Trial: Mirena or Conventional Medical Treatment for Menorrhagia

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: MiCo - Mirena or Conventional Medical Treatment for Menorrhagia

Brief Summary:

The aim of this prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Mirena in treatment of prolonged or heavy menstrual bleeding (Menorrhagia) under daily-life treatment conditions.

It is planned to conduct the study in about 10 countries with a total of 1000 patients. In several countries, a comparator group will also be documented.

For each patient, an initial visit and one to three follow-up visits after about 3, 6 and 12 months will be documented by the treating physician on the case report form. Observations include the patient's demographic parameters (date of birth, height, weight, race and smoking habits), previous contraceptives and menorrhagia treatment, gynaecological history, baseline menstruation, result of insertion, concomitant medications and diseases as well as menorrhagia symptoms. Overall treatment success will be evaluated at the end of treatment including number of weeks until improvement and reduction of menstrual bleeding with respect to duration and severity, and patient's satisfaction.


Detailed Summary:

The "MiCo - Mirena or conventional medical treatment for menorrhagia" study consist of two parts, MiCo Asia-Pacific and MiCo MA0901 (Rest of World).

Data from both parts will be analysed in separate pools as well as in a global pool. The trial alias are IMPACT Nos. 14697, 14536 (NCT01085487).


Sponsor: Bayer

Current Primary Outcome: Cumulative continuation rate stratified by history of previous treatment(s) for menorrhagia [ Time Frame: at 12 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Bleeding pattern [ Time Frame: at 12 months ]
  • Patient satisfaction at end of documentation [ Time Frame: at 12 months ]
  • Impact of the therapy in terms of patient-derived health outcomes (validated patient questionnaire) [ Time Frame: at 12 months ]
  • Adverse events collection [ Time Frame: at 12 months ]


Original Secondary Outcome: Same as current

Information By: Bayer

Dates:
Date Received: March 17, 2009
Date Started: November 2008
Date Completion:
Last Updated: June 30, 2015
Last Verified: June 2015